Welcome to AZ MedX

AstraZeneca’s Respiratory & Immunology medical resource centre for healthcare professionals

Discover the latest advances and approaches in asthma, COPD and more

This site is intended for the use of Healthcare Professionals only. By clicking the link below you declare and confirm:

If you are not a Healthcare Professional, please follow this link for information on global patient resources.

What is the CHRONICLE Study?

The CHRONICLE study is a long-term prospective observational study of disease characteristics, treatment patterns and health outcomes in individuals with severe asthma who do not achieve control with high-dose inhaled corticosteroid (ICS) therapy with additional controllers and/or require systemic corticosteroid or monoclonal antibody therapy.

The study, sponsored by AstraZeneca, aims to provide a contemporary view of the epidemiology and management of severe asthma in the United States. Patients (≥18 years old; ≥12 months diagnosis of severe asthma) will meet one of the three following treatment criteria for severe asthma:

  1. Received systemic corticosteroids or other systemic immunosuppressants over ~50% or more of the prior 12 months.
  2. Uncontrolled on asthma treatment consistent with the GINA Step 4 or 5, receiving high-dose ICS with additional controllers.
  3. Current use of an FDA-approved monoclonal antibody agent for treatment of severe asthma.

If you would like more information on the CHRONICLE study, contact the AstraZeneca Information Center or take a look at the AstraZeneca clinical trials website.

Study Design


  • ≥18 years
  • ≥12 months diagnosis of severe asthma
  • Meet study criteria for severe asthma treatment



  • 4000 patients enrolled across multiple academic and community-based specialist centres by asthma treating specialists (e.g., allergists and pulmonologists).



  • Information from medical records and specialists at baseline and every 6 months
  • Patient completed web-based disease characteristics and quality of life patient surveys at baseline, monthly, every 3 months and every 6 months depending on the specific endpoint.



  • Patients will be followed until study discontinuation, patient withdrawal or death, whichever occurs first (expected to be at least 3 years).


ClinicalTrials.gov Identifier: NCT03373045

Recruitment status: Recruiting


You are now leaving: http://azmedx.com/

By following this link you will be leaving the AZ MedX website.

Please note that AstraZeneca does not take responsibility for the content displayed on other websites.

Continue Return to AZ MedX